Open AccessVirus Neutralization by Human Intravenous Immunoglobulin Against Influenza Virus Subtypes A/H5 and A/H7
Author(s) -
Ritsuko KubotaKoketsu,
Mikihiro Yunoki,
Yoshinobu Okuno,
Kazuyoshi Ikuta
Publication year - 2021
Publication title -
biologics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 38
eISSN - 1177-5491
pISSN - 1177-5475
DOI - 10.2147/btt.s291808
Subject(s) - virology , virus , antibody , influenza a virus subtype h5n1 , neutralization , influenza a virus , biology , avian influenza virus , vaccination , pandemic , medicine , covid-19 , immunology , infectious disease (medical specialty) , disease , pathology
Highly pathogenic avian influenza viruses are a threat to human health. Although donor populations have not experienced pandemic, they have been immunized by natural infections and/or vaccinations of influenza viruses such as A/H1N1, A/H3N2, and B. Therefore, it is considered that human intravenous immunoglobulin (IVIG) derived from healthy donors does not include IgG against avian influenza viruses. However, cross-reactivity has not been evaluated yet. In this study, cross-reactivity against the avian influenza virus A/H5N1, A/H7N1, A/H7N2, A/H7N7, A/H7N9, and A/H10N9 was evaluated.